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Abstract
Statistical methods for detecting adverse drug reactions (ADRs) resulting from drug-drug
interactions (DDIs) have been used in recent years to analyze the datasets in spontaneous
reporting systems. We provide the SignalDetDDImacro in SAS to calculate the criteria
for detecting ADRs resulting from the concomitant use of two drugs. We outline two criteria
for detecting DDIs with the combination of two drugs and illustrate the implementation of the
macro by way of an example. To implement the macro, a user specifies the target ADR and
the two drugs to be evaluated. The SignalDetDDImacro outputs a table showing the
number of reports on ADRs, the values of the two criteria for detecting ADRs, and the pres-
ence of DDIs. This macro enables users to easily and automatically assess the clinical DDIs
that result from ADRs. The SignalDetDDImacro is freely available in the Supporting
Information.
Introduction
Polypharmacy, which is the use of multiple concomitant drugs to treat a medical condition, is
recognized as a serious health, economical, and social problem. In particular, approximately
30% of elderly patients take six or more drugs concurrently [1]. The concomitant use of two or
more drugs increases the risk of adverse drug reactions (ADRs). This problem is generally
known as drug-drug interactions (DDIs), which are accurately defined as a “change in the
effect of one drug in the presence of another drug, herbal medicine, food, drink, or environ-
mental chemical agent” [2].
Spontaneous reporting systems are a crucial source of drug safety surveillance data and are
commonly used to detect suspected ADRs and to generate the hypothesis of new ADRs in
real-world settings. Authorities have been preparing databases for spontaneous reporting sys-
tems since the 1960s. Examples of these databases include: 1) the VigiBase, which is the world’s
largest database, and is maintained by the WHO Collaborating Centre for International Drug
Monitoring in Uppsala, Sweden; 2) the US Food and Drug Administration (FDA) Adverse
Event Reporting System (FAERS), which is the database for products marketed in the US; 3)
the EudraVigilance, which is a central database created by the European Medicines Agency in
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2001; and 4) the Japanese Adverse Drug Event Report database, which is maintained by the
Japanese Pharmaceuticals and Medical Devices Agency.
Statistical methods are needed to analyze ADRs resulting from the concomitant use of
drugs, and to screen spontaneous reporting systems for possible DDI signals. Some researchers
use a logistic regression model including the use of one drug D1 and another drug D2 as factors
and an interactive term to indicate the concomitant use of both drugs [3, 4]. Thakrar et al.
(2007) [5] also applied a multiplicative model (also known as a log-linear model) and an addi-
tive model (also referred to as a linear probability model) to general signals of DDIs by includ-
ing an interactive term in the same manner as above. Computerized algorithms using these
statistical methods were developed to detect DDIs automatically [6–8]. In addition, Nore´n
et al. [9] developed a novel statistical method for DDI detection using the observed to expected
ratio of the number of reports for ADRs for a combination of two drugs. This method is based
on the 2.5th percentile of a disproportionality measure (O025), which is a shrinkage approach
towards no association with the aim of reducing the false positive rate. Currently, the criterion
O025 is frequently applied to databases to detect DDIs and computerized algorithms using this
criterion are being developed for the automated detection of potential DDIs in spontaneous
reporting systems [7, 8] Recently, Gosho et al. [10] proposed another statistical criterion to
detect the DDIs that cause ADRs. The criterion is based on the chi-square statistics with
Yates’s correction. Although Nore´n et al. [9] and Gosho et al. [10] introduced statistical meth-
ods for DDI detection and their properties, they did not mention the practical procedure and
implementation of these methods to apply the databases for spontaneous reporting systems.
Further, they did not show a concrete way to preprocess and clean datasets derived from the
spontaneous reporting systems necessary for applying the methods. In addition, they did not
provide computational algorithms to implement the methods using standard statistical
software.
In this paper, we present a new SAS macro to calculate the values of the criteria proposed
by Nore´n et al. [9] and Gosho et al. [10] for screening the ADRs resulting from the combined
use of two drugs recorded in spontaneous reporting systems. We additionally provide SAS
programs to preprocess and clean the datasets derived from the spontaneous reporting sys-
tems, which directly and automatically implement the methods for DDI detection. We also
apply the macro to analyze the FAERS database. The use of this SAS macro enables the facile
and automatic screening of clinical DDIs resulting in ADRs. The macro (SignalDetDDI)
runs in the Microsoft Windows environment and requires SAS 9.3 (at least the SAS/BASE and
the SAS/STAT components) or above.
Design and implementation
Definition of drug-drug interactions
A DDI is defined as occurring in a situation in which “the effects of one drug, D1, increase in
the presence of another drug, D2.” The interaction is denoted as the interdependence between
the effects of two drugs, and is considered to be synergistic [9]. The interaction is exclusive of
the additive effects of the two drugs. Our focus in this study was to detect whether synergistic
interactions occurred between two drugs.
Let “ADR A” denote an adverse drug reaction “A” of interest. n111 represents the number of
reports on ADR A listing both D1 and D2, n101 denotes the number of reports on ADR A listing
D1, but not D2, n011 signifies the number of reports on ADR A listing D2, but not D1, and n001
denotes the number of reports on ADR A in the absence of both D1 and D2. The incidence of
probability of ADR A, the number of ADR reports excluding ADR A, and the total number of
reports are listed in Table 1.
SAS macro for screening adverse drug-drug interactions
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We focused on the additive assumption for DDIs [5]. When no interaction is detected
under the additive assumption, the excess risk associated with D1 in the absence of D2 is the
same as the excess risk associated with D1 in the presence of D2. In this case,
RDD1D2 ¼ RDD1 þ RDD2 , where RDD1 ¼ p10   p00, RDD2 ¼ p01   p00, and RDD1D2 ¼ p11   p00.
Thus, p11 − p10 − p01+ p00 = 0. In the event of a positive interaction, the assumption is that this
measure is greater than 0. The criteria proposed by Nore´n et al. [9] and Gosho et al. [10] are
structured with the purpose of detecting the additive risk.
Criteria for detecting adverse drug reactions
Nore´n et al. [9] proposed a criterion to detect suspected DDIs in databases containing sponta-
neous reports. This method is based on a measure calculated as the ratio of the observed
reporting rate, f11, of an ADR resulting from the combination of two drugs and its expected
value, E[f11]. The expected value is always unknown and should be estimated.
Let
f00 ¼
n001
n00�
; f10 ¼
n101
n10�
; f01 ¼
n011
n01�
; f11 ¼
n111
n11�
The estimator g11 of E[f11] is given as follows [9]:
g11 ¼ 1  
1
max
f00
1   f00
;
f10
1   f10
� �
þmax
f00
1   f00
;
f01
1   f01
� �
 
f00
1   f00
þ 1
ð1Þ
Nore´n et al. [9] provided a measure for detecting ADRs with two drugs:
O ¼ log
2
n11 þ 0:5
E111 þ 0:5
; ð2Þ
where E111 = g11n11�. The O measure can be motivated from both frequentist and Bayesian per-
spectives. In the frequentist approach, the measure for signal detection is given as follows:
O025 ¼ O  
�ð0:975Þ
ln ð2Þ ffiffiffiffiffiffiffin111
p ; ð3Þ
where ϕ(0.975) is the 97.5th percentile of the standard normal distribution. With the Bayesian
approach, the lower limit, O025, of the exact two-sided 95% credibility interval for O in Eq (2)
can be numerically estimated [9]. In both the frequentist and Bayesian approaches, O025 > 0 is
used as a threshold to screen for signal under the combination of two drugs [9], with O025 for
these two approaches denoted as O025F and O025B, respectively.
Gosho et al. [10] proposed another criterion to screen the ADR resulting from the concomi-
tant use of two drugs. Gosho et al. [10] prepared the following measure, χ, to estimate the dis-
crepancy between the observed and expected number of events with specific drug
Table 1. Four-by-two contingency table for DDI evaluation.
Number of events
(Incidence probability for ADR A)
ADR A Not ADR A Total
Neither D1 nor D2 n001 (p00) n000 n00�
Only D1 n101 (p10) n100 n10�
Only D2 n011 (p01) n010 n01�
D1 and D2 n111 (p11) n110 n11�
https://doi.org/10.1371/journal.pone.0207487.t001
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combinations:
w ¼
n111   E111   0:5ffiffiffiffiffiffiffiffi
E111
p ð4Þ
The expected number of events, E111, can be estimated using Eq (1) and χ is the square root
of the chi-square test statistics with a corretion term “0.5”. In Eq (4), χ is the criterion that
directly measures the discrepancy between the observed and expected number of reports in
drug combinations to which Yates’s correction has been applied to avoid the small-sample
issue. Ultimately, χ> 2 is used as a threshold to screen for a signal resulting from the concomi-
tant use of two drugs.
The methods proposed by Nore´n et al. [9] and Gosho et al. [10] focus on the detection of
synergistic interaction effects. Inversely, these methods are not designed to detect antagonistic
effects. Thus, our SAS macro (SignalDetDDI) highlights only the synergistic rather than
the antagonistic effects.
Working with the macro
The SignalDetDDImacro is included with this article in the file SignalDetDDI.sas.
The arguments taken by the macro are summarized in Table 2. As shown in the table, the
names of datasets for ADRs and drugs that are generated from the database in spontaneous
reporting systems (AE_INDS and DRUG_INDS, respectively), the name of the dataset that
stores an ADR and the two drugs to be analyzed for signal detection (LIST_INDS), the
name of a variable identifying each patient (ID), the names of variables for the ADR and
drug (AE_NAME and DRUG_NAME, respectively), and the name of a variable representing
the sequence in each patient (DRUG_SEQ), should be specified for implementing the
macro.
The SignalDetDDImacro consists of three nested macros, DataHandling, Sig-
nalDS, and Signal. The DataHandlingmacro generates the analysis datasets using the
datasets specified at AE_INDS and DRUG_INDS, for signal detection. The SignalDSmacro
calculates the number of reports shown in Table 1, i.e., n001, n000, n101, n100, n011, n010, n111,
and n110, in the case when an ADR and the use of two drugs are identified. The Signal
macro provides the values of the criteria (O025F, O025B, and χ) for screening the ADRs resulting
from the concomitant use of two drugs.
Table 2. Arguments for implementing SignalDetDDImacro.
Argument Description Note
AE_INDS Name of the SAS dataset storing
ADRs
The dataset can be SAS. The data structure is illustrated in
Table 3.
DRUG_INDS Name of the SAS dataset storing
drugs
The dataset can be SAS. The data structure is illustrated in
Table 4.
LIST_INDS Name of the SAS dataset storing
the ADR and two drugs
An ADR and two drugs with one or more record to be analyzed
for signal detection, can be specified. The dataset can be SAS.
The data structure is illustrated in Table 5.
ID Name of the variable identifying
each patient
Character and numerical types are available.
AE_NAME Name of the ADR variable
DRUG_NAME Name of the drug variable
DRUG_SEQ Name of the sequence variable
(within a patient)
Character and numerical types are available.
https://doi.org/10.1371/journal.pone.0207487.t002
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Datasets for implementation of the macro
A user can call the SignalDetDDImacro by inputting the arguments listed in Table 2.
Before the user implements the macro, they would need to prepare three SAS datasets in
which to store the ADRs, drug, and the target ADR and the two drugs to be evaluated,
respectively.
The ADRs are stored in aeds, which is a dataset provided by the FAERS database and is
partially reproduced in Table 3. The aeds data include the case number, primaryid; a
within-subject observation identifier, ae_seq; and the name of the ADRs reported, ae. The
identifier ae_seq is not necessary for implementing the macro.
The drugds, which is a dataset provided by the FAERS database, is used to store the drug,
and is partially reproduced in Table 4. The drugds data include the case number, pri-
maryid; a within-subject observation identifier, drug_seq; and the name of drugs
reported, drug. All three variables are necessary for implementing the macro.
The listds data in Table 5 store the target ADR adr and the two drugs d1 and d2 to be
evaluated. All three variables are necessary for implementing the macro. This dataset can con-
tain data originating from one or more records.
Output of the macro
The macro creates an output table that includes n001, n000, n101, n100, n011, n010, n111, and n110
in Table 1, where the ADR and two drugs are specified by the user. The output table also
Table 3. Example of a dataset of three patients for the aeds data.
primaryid ae_seq ae
100033062 1 Cough
100033062 2 Throat irritation
100033073 1 Rhinorrhoea
100033083 1 Malaise
100033083 2 Unevaluable event
https://doi.org/10.1371/journal.pone.0207487.t003
Table 4. Example of a dataset of three patients for the drugds data.
primaryid drug_seq drug
100033062 1 LETAIRIS
100033062 2 TYVASO
100033073 1 LETAIRIS
100033073 2 LETAIRIS
100033083 1 LETAIRIS
100033083 2 LETAIRIS
https://doi.org/10.1371/journal.pone.0207487.t004
Table 5. Example of a dataset for analyzing the ADR (adr) for the concomitant use of two drugs (d1 and d2) for
the listds data.
adr d1 d2
hypoglycaemia sitagliptin nateglinide
hypoglycaemia sitagliptin repaglinide
hypoglycaemia sitagliptin miglitol
https://doi.org/10.1371/journal.pone.0207487.t005
SAS macro for screening adverse drug-drug interactions
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contains the value of the criteria (O025F, O025B, and χ) for screening the ADR for the concomi-
tant use of the two drugs and the decision flag of the signal. The flag has the value “Y” or “N”
to indicate whether the signal is detected using the three criteria. The details of the output are
shown in the Results section.
Results
We applied the SignalDetDDImacro to the FAERS and evaluated the risk of hypoglycae-
mia as an ADR (adr) for the three combinations of two diabetic drugs (d1 as d2) shown in
Table 5. Drug-induced hypoglycemia is the commonest adverse event and the most important
complication of antidiabetic medications. DDIs are also one of the exogenous risk factors of
iatrogenic hypoglycemia (e.g., [11, 12]). Sitagliptin is a selective dipeptidyl peptidase-4 inhibi-
tor for the treatment of patients with type 2 diabetes and is sometimes used in combination
with other classes of antidiabetic agents such as glinides (e.g., mitiglinide and repaglinide) and
α-glycosidase inhibitors (e.g., miglitol).
Datasets
The FAERS is a database that contains reports about adverse events and medication errors, as
well as complaints about product quality resulting in adverse events that were submitted to the
FDA [13]. The database is designed to support the FDA’s post-marketing safety surveillance
program for drug and therapeutic biologic products. Adverse events and medication errors are
coded using the terms in the Medical Dictionary for Regulatory Activities (MedDRA) terminol-
ogy [13]. The database is managed by the FDA, contains information that has been entered
since 2004, and is updated quarterly. The structure of the database basically complies with the
international safety reporting guidelines (International Conference on Harmonization E2B). It
comprises seven data files: patient demographics, drug information, indication, case outcome,
reactions/events, report source, and therapy. The name of the ADR is defined in the MedDRA
as the preferred term. Standardized MedDRA Queries (SMQs) are not supported in the data-
base. The drug name is a combination of the brand (trade), generic, and general names of drugs.
We provide the supportive SAS program file Supplement macro for handling
FAERS data files.sas in S1 Appendix. The file includes four SAS macros. The first
macro is designed to prepare the SAS datasets by the indicated time ranges and converts the
FAERS raw data files posted on the FDA website into the SAS datasets. The raw data files can be
downloaded from the website [13]. The user can implement the macro by specifying the period
of interest for which they require data from the database. The second macro allows the aeds
and drugds datasets to be prepared for implementation of the SignalDetDDImacro. The
macro also combines the datasets according to each period derived from the first macro. The
third and fourth are example macros that replace the brand name(s) of a target drug with the
general name in the drugds dataset for the implementation of the SignalDetDDImacro.
Before implementing these macros, the user needs to specify the general (ingredient) name of
the two target drugs to be analyzed. Using the RxNav system based on RxNorm (https://mor.
nlm.nih.gov/RxNav/), the names of each drug are tabulated as a CSV file. After storing the CSV
files in an appropriate folder, the user can implement the third macro by specifying the names
of each CSV file and the pass name in which the files are stored. After implementing the third
macro, the user can replace the brand name(s) with the general name by using the forth macro.
We downloaded data from the FAERS database for the period 2017 Q1 to Q4 via the FDA
website [13] and generated the aeds and drugds datasets using the Supplement macro
for handling FAERS data files, which we then analyzed. The aeds dataset con-
tains 4,017,430 adverse reactions and drugds contains 4,863,924 drug information records.
SAS macro for screening adverse drug-drug interactions
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Implementation of the macro
The implementation of the SignalDetDDImacro is demonstrated using the aeds,
drugds, and lisitds data. The code for implementing the SignalDetDDImacro, code
for calling the macro and generating the listds, and code for generating the aeds and
drugds (Supplement macro for handling FAERS data files) are given in S1
Appendix. The user implements the SignalDetDDImacro by inputting values for the vari-
ous arguments as shown in the code below (also see Table 2) and invokes the macro.
%SignalDetDDI (AE_INDS = aeds, DRUG_INDS = drugds,
LIST_INDS = listds, ID = primaryid, AE_NAME = ae,
DRUG_NAME = drug, DRUG_SEQ = drug_seq);
Output and result
Table 6 shows the output results of the macro. In Table 6, “ADR” is the specified ADRs, and
“Drug1” and “Drug2” are the names of the two drugs to be analyzed for detecting the ADRs.
Further, “n000”, “n001”, “n100”, “n101”, “n010”, “n011”, “n110”, and “n111” are the number
of reports for the ADRs and two drugs defined in Table 1, “E111” is the estimated E111 in Eq
(1), and “Omega025F,” “Omega025B,” and “Chi” refer to the criteria values for signal detection
given in Section 1. When the criteria values cannot be calculated, they are displayed as “NC.”
“Signal by Omega025F?,” “Signal by Omega025B?,” and “Signal by Chi?” are the decision of
the signal using the three criteria, O025F, O025B, and χ, respectively. If the signal is detected,
then the value is “Y”, otherwise it is “N.” As mentioned earlier, when O025F and O025B are
greater than 0 and χ is greater than 2, a signal is considered to have been detected. Finally,
“Warning” is a message that is output only when the criteria values could not be calculated
and displays the reason why the values were not calculated.
In this example, the concomitant use of sitagliptin and nateglinide was noted using the
O025F, O025B, and χ for hypoglycaemia. The criteria values for O025F, O025B, and χ resulting
from the concomitant use of sitagliptin and miglitol cannot be calculated because “n111”
(n111)’, the number of reports of hypoglycaemia using both of these two drugs, is zero. As the
subset of the database from the FAERS used in this analysis is quite small, the results should be
considered illustrative; thus, one should not infer that this result is obviously invalid.
Availability and future directions
The research presented in this paper led to the development of the SignalDetDDImacro to
calculate the values of the criteria (O025F, O025B, and χ) for detecting clinical adverse DDIs in
Table 6. Outputs of analysis for implementing the SignalDetDDImacro.
ADR Drug1 Drug2 n000 n001 n100 n101 n010 n011 n110 n111 E111
hypoglycaemia sitagliptin nateglinide 1360164 3005 6677 105 168 0 21 5 0.40
hypoglycaemia sitagliptin repaglinide 1359906 2941 6639 109 426 64 59 1 8.48
hypoglycaemia sitagliptin miglitol 1360292 3003 6696 110 40 2 2 0 0.12
Omega025F Omega025B Chi Signal by Omega025F? Signal by Omega025B? Signal by Chi? Warning
1.34 1.25 6.46 Y Y Y
−5.41 −6.23 −2.74 N N N
NC NC NC N N N n111 = 0
https://doi.org/10.1371/journal.pone.0207487.t006
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spontaneous reporting systems. All the SAS codes are freely available (S1 Appendix). This
macro enables researchers of pharmacoepidemiology and drug safety to analyze big data from
spontaneous reporting systems in a facile and automatic manner. In any signal detection anal-
ysis, the risk of false positives and false negatives for adverse DDIs exists. In other words, a sig-
nal for DDIs is either falsely detected or missed. It should be kept in mind that the false
positive and false negative rates cannot be zero simultaneously.
The SignalDetDDImacro has the following practical limitations. Before the macro can
be implemented, the user would have to preprocess and clean the datasets aeds and drugds
because databases in spontaneous reporting systems provided by the authorities are typically
not subjected to data management. For example, these databases often include a mixture of
brand (trade), generic, and general names of drugs. TheSupplement macro for han-
dling FAERS data files.sas is helpful to convert brand names to general names.
Another limitation is that drugs that aim to inhibit adverse effects of other drugs may be diffi-
cult to distinguish in this system (e.g., anticancer drugs and anti-emetics). Moreover, this
macro cannot be directly used to screen DDIs among three or more drugs.
Supporting information
S1 Appendix. All SAS codes are provided.
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